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Practice points
• Standard of care is lacking regarding the best approach in treating patients with symptomatic intracranial
BRAF-mutated melanoma.
• Symptomatic patients with intracranial metastatic melanoma are often treated with dexamethasone to control
brain edema.
• The use of steroids at baseline can decrease the antitumor efficacy of immune checkpoint blockade (ICB) and lead
to poor outcomes.
• Objective response to ICB in symptomatic metastatic intracranial melanoma is low and is associated with short
duration of response.
• Objective response rate to combined BRAF-MEK inhibitors in BRAF-mutated intracranial melanoma is high, albeit
short duration of response prior to progression.
• Presence of mutations such as CDKN2A is associated with a shorter duration of response to BRAF-MEK inhibitors
in patients with BRAF-mutated melanoma.
• Preclinical and clinical data suggest the efficacy of ICB might be compromised in patients who receive ICB after
progressing during treatment with BRAF-MEK inhibitors.
• Using BRAF-MEK inhibitors (short course) in BRAF-mutated symptomatic intracranial metastatic melanoma might
allow the discontinuation of steroids and lead to higher intracranial response. This might optimize the effect of
ICB if started prior to progression of the disease.

The introduction of immune checkpoint blockade (ICB) and BRAF-MEK inhibitors has substantially improved outcomes in patients with metastatic melanoma. However, several challenging factors may hinder
the efficacy of ICB in patients with symptomatic intracranial metastatic melanoma who are immunosuppressed due to the use of steroids prior to the administration of ICB. This has resulted in the exclusion
of patients treated with high dose steroid at baseline from the majority of ICB clinical trials. In addition,
despite the high efficacy of BRAF-MEK inhibitors in BRAF-mutant intracranial metastatic melanoma, most
tumors will eventually progress. This demonstrates a gap in addressing the best management in such
patients. Here, we present a case demonstrating our approach in this patient population.
Tweetable abstract: Management of symptomatic BRAF-mutated intracranial melanoma.
First draft submitted: 10 November 2020; Accepted for publication: 21 January 2021; Published online:
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Melanoma brain metastases represent a unique spectrum of metastatic melanoma due to high associated morbidity
and mortality. This is of importance as a high proportion of patients (∼36%) have evidence of intracranial metastases
at the time of diagnosis [1]. Survival has improved significantly with the introduction of immune checkpoint blockade
(ICB) and BRAF-MEK inhibitors. However, some patients have a high disease burden (defined as ≥3 intracranial
lesions), and often demonstrate neurological symptoms. These cases represent a challenge in clinical practice as
most clinical trials excluded patients with symptomatic brain metastases. Moreover, the immunosuppressive state
caused by baseline use of dexamethasone, which is used to relieve neurological symptoms and brain edema, can
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attenuate the response to ICB and lead to poorer responses and outcomes [2–5]. Furthermore, despite the high
efficacy of targeted treatment with combination BRAF and MEK inhibitors in intracranial metastatic BRAFmutated melanoma, most tumors will eventually progress due to acquired resistance. Genomic alterations such
as the loss of expression of CDKN2A can contribute to acquired resistance leading to a short-lived response to
targeted therapy [6,7]. Therefore, the heterogenous molecular nature of melanoma could further compromise the
duration of response to targeted therapy. Here, we report the case of a patient successfully treated with planned
sequential BRAF-MEK inhibitors followed by ICB after presenting with high-burden, symptomatic intracranial
metastatic melanoma requiring high dose dexamethasone. The patient had detectable BRAFV600E and CDKN2A
mutations. The treatment course included administration of BRAF-MEK inhibitors for 8 weeks while discontinuing
dexamethasone followed by ipilimumab-nivolumab administration. The patient had a near-complete radiological
resolution of intracranial disease after initiating ICB with an ongoing durable response at 8 months of follow-up.
Case presentation
A 50-year old female presented with new left arm weakness, headache, slurred speech and vision disturbance. Her
past medical history was significant for stage IA melanoma in the left chest wall diagnosed 5 years prior for which
she underwent wide local excision. She had another lesion in the left lower extremity 2 years later consistent with
malignant melanoma (Stage IB: T1bN0M0), which was treated with wide local excision and sentinel lymph node
biopsy. The patient underwent brain magnetic resonance imaging (MRI) due to presence of neurological symptoms
which showed numerous scattered lesions (30 lesions) involving the supratentorial and infratentorial compartments
bilaterally, consistent with metastatic disease (Figure 1A). The patient was started on dexamethasone (4 mg orally,
three-times daily) due to symptomatic vasogenic edema (Figure 2A). Chest computed tomography (CT) revealed a
3 cm right upper lobe pulmonary mass which was biopsied and confirmed malignant melanoma. Next-generation
sequencing revealed presence of a BRAFV600E mutation (VAF 41.1%), CDKN2A copy number loss, and tumor
mutation burden of 11.1 mutation per megabase (Tempus xT assay). The patient completed whole brain radiation
WBRT (total of 30 Gy over 10 fractions) prior to referral to our hospital for further evaluation and management.
Repeat brain MRI confirmed persistence of intracranial metastatic lesions. We tapered off dexamethasone within
3-week period after starting treatment with BRAF inhibitor (encorafenib 300 mg once daily orally) and MEK
inhibitor (binimetinib 45 mg twice daily orally) as a bridge to control the symptomatic brain lesions prior to
initiation of ICB. There were no side effects noted during treatment, and brain MRI after 8 weeks demonstrated
partial response in several lesions without new neurological symptoms (Figure 1B). There was also continued
resolution of brain edema after starting targeted therapy (Figure 2B). CT showed partial response in pulmonary
metastatic lesion. Encorafenib and binimetinib were discontinued 8 weeks after their initiation despite no evidence
of progressive disease, and the patient switched to ICB combination therapy including ipilimumab (3 mg/kg
intravenously) and nivolumab (1 mg/kg intravenously) every three weeks. Given the risk of rebound disease and
flare-up after the discontinuation of targeted therapy, the patient was closely monitored in the clinic but did not
demonstrate any concerning signs or symptoms. After the second cycle of ICB, there was near-complete resolution
noted on brain MRI. In addition, repeat CT demonstrated complete resolution of the pulmonary metastatic lesion.
The patient developed hepatitis (immune related adverse event grade 3) which required holding off ICB and
a treatment with 4-week course of high-dose prednisone taper (started 1 mg/kg/day). The patient later started
maintenance ICB therapy with nivolumab (480 mg intravenously every 4 weeks). She remains without neurological
symptoms and brain MRI continues to show a durable response in intracranial brain metastases after 8 months of
initiating treatment (Figure 1C).
Discussion
The integration of ICB into the treatment paradigm of patients with intracranial metastatic melanoma has
substantially improved overall survival compared with the pre-immunotherapy era based on data collected from
the national cancer database [1]. Further prospective trials have corroborated the high and durable efficacy of ICB
in intracranial metastatic melanoma. One such example is the CheckMate-204 Phase II open-label trial, which
prospectively evaluated combination ICB (ipilimumab and nivolumab) followed by maintenance nivolumab in 94
patients with asymptomatic intracranial metastases [8]. This trial demonstrated a high intracranial response rate
of 57% (including complete and partial responses) which was similar to the extracranial metastatic response rate.
Moreover, the estimated overall survival rate was 81.5% at 1-year which further substantiated the evidence of
the intracranial durable response attained through treatment with ICB [8]. Nevertheless, the evidence supporting
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After 8 months of therapy

Figure 1. Brain MRI demonstrating intracranial metastatic changes during treatment of the patient in the case
report. (A) Axial section of brain MRI in T1 post contrast phase prior to treatment with BRAF-MEK inhibitors which
demonstrates 30 scattered enhancing lesions in the supratentorial and infratentorial compartments bilaterally with
associated edema. (B) Demonstrates reduction in the size and the number of several lesions 8 weeks after treatment
with BRAF-MEK inhibitors and prior to administration of immunotherapy. (C) Marked decrease in the size of bilateral
cerebral and cerebellar metastatic lesions with near-complete resolution of several lesions after 6 months of
treatment with ICB.
ICB: Immune checkpoint blockade.

the use of ICB in patients with high burden symptomatic intracranial metastatic melanoma and those who are
treated with a high dose of steroids at baseline is lacking as most clinical trials have excluded patients with the
previous characteristics. This stems from the notion that immunosuppression at baseline (including the use of
steroids) could reduce the antitumor efficacy of ICB and lead to short-lived response. To this end, another cohort
of the CheckMate-204 study addressed this issue by evaluating the efficacy of ipilimumab and nivolumab in 18
patients with symptomatic melanoma brain metastases of which 39% had three or more brain lesions and 61%
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Figure 2. Brain MRI demonstrating with FLAIR signal demonstrating brain edema. (A) Axial section of brain MRI
with FLAIR signal showing large diffuse signal abnormality throughout the brain prior to treatment with steroids. (B)
Significant reduction of the signal abnormality at end of treatment with BRAF-MEK inhibitors.

were on dexamethasone (4 mg or less) [9]. The results demonstrated an objective response rate (ORR) of 22%
which was inferior to the response rate observed in patients with asymptomatic brain metastases and those who are
not receiving steroids at baseline (ORR = 57%) [9].
Interestingly, BRAF-MEK inhibitors have an advantage over ICB given the high response rates in patients with
both asymptomatic and symptomatic intracranial metastatic melanoma whose tumors harbor BRAFV600 mutations
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(>50 and 59%, respectively) [10]. Nevertheless, the high response rates in intracranial metastases are temporary,
as the majority of patients treated with targeted therapy progress eventually, which is likely secondary to acquired
resistance mechanisms [10,11]. The presence of CDKN2A copy number loss has been suggested to contribute
to resistance to BRAF-MEK inhibitors in melanoma and lead to a shorter duration of response and inferior
outcomes [6,7,12]. In addition, the duration of response in intracranial melanoma metastases is shorter compared
with extracranial disease [10,13,14]. Of importance, one concern upon discontinuation of BRAF-MEK inhibitors is
the rebound effect caused by reactivation of the BRAF kinase which could result in a flare-up and worsening of
the metastatic disease [15]. Collectively, the previous evidence supports the high efficacy of BRAF-MEK inhibitors
in patients with BRAFV600E melanoma brain metastases, albeit short duration of response with early progression
during treatment and the concern of possible flare-up upon discontinuation of targeted therapy.
Our case highlights the challenge often encountered in clinical practice when making a decision to treat patients
with BRAF-mutated and symptomatic intracranial metastatic melanoma who are receiving baseline high dose
steroids. The use of ICB as a front-line therapy in these patients is expected to be associated with low efficacy and
short durable response based on the available evidence. As such, BRAF-MEK inhibitors in these patients can offer
an advantage in obtaining high response as their efficacy is not compromised by steroids. However, the obtained
response with targeted therapy is sustained for a short period prior to progression. Therefore, we followed an
approach using BRAF-MEK inhibitors as a bridge to allow the discontinuation of glucocorticoid and to obtain a
response in the intracranial metastatic disease prior to initiating ICB (evidenced by the partial radiological response,
decrease in intracranial lesion numbers and control of neurological symptoms). We hypothesized such an approach
would allow the resolution of the immunosuppressive effect of steroids and optimize the response to ICB. The
presence of CDKN2A copy number loss further supported our rationale to use BRAF-MEK inhibitors temporarily
given the short duration of response associated with this genetic alteration [6,7]. It should be noted that whole-brain
radiotherapy could have contributed to the response obtained in the intracranial disease, however, we believe that
most of the benefit obtained in the intracranial disease in our case was secondary to the use of BRAF-MEK
inhibitors given the depth of response.
Recently, there has been an increased interest in evaluating the use of BRAF-MEK inhibitors with ICB in
the treatment of metastatic melanoma. These efforts are assessing several approaches in clinical trials including
combination targeted and immunotherapy or the sequential use of BRAF-MEK inhibitors followed by ICB and is
summarized in Table 1 [16–21]. This is based on the role of BRAF-MAPK pathway in the modulation of the tumor
biology in melanoma. Preclinical research supports this notion as BRAFV600E mutant melanoma is associated with
immunosuppressive tumor microenvironment leading to diminished antigen presentation and decreased CD8+
T cells [22]. As such, inhibition of the BRAF-MAPK pathway can alter tumor microenvironment favoring an
immune permissive effect, which can facilitate the action of ICB [23]. To this end, the concurrent use of BRAFMEK inhibitors and ICB or the sequenced use could favor a higher response with improved survival and is currently
under investigation. Of importance, it has been suggested that when using an approach utilizing targeted therapy
followed by ICB, waiting until progression while on BRAF-MEK inhibitors prior to starting immunotherapy could
lead to an immunosuppressive environment and downregulation of effector T cells, which could negatively impact
the efficacy of ICB [24]. This further supports our approach of switching BRAF-MEK inhibitors to ICB prior to an
evidence of progressive disease in our patient.
The preclinical evidence of the compromised outcome with ICB treatment in patients who progressed on BRAFMEK inhibitors has been echoed by a recent Phase-II trial (ABC trial), which evaluated the efficacy of ICB in 76
patients with melanoma brain metastases [25]. This study included a cohort of 16 patients with symptomatic or
leptomeningeal brain metastases of which 75% received ICB treatment after they progressed while on BRAF-MEK
inhibitors, and were found to have low response rates (ORR = 6%, progressive disease 81%) [25].
Conclusion
This report describes a patient with BRAF-mutant symptomatic intracranial metastatic melanoma who was successfully treated with BRAF-MEK inhibitors as a bridge to allow discontinuation of steroids prior to ICB therapy.
The patient had significant clinical and radiographic response ongoing at 8 months after initiating therapy. Our
observation with the previous reported literature suggest: treatment with BRAF-MEK inhibitors may allow the
discontinuation of steroids in patients with symptomatic BRAF mutant intracranial metastatic melanoma; bridging
temporarily with BRAF-MEK inhibitors prior to evidence of progressive disease may optimize the efficacy of ICB
and lead to a durable response; and; integration of tumor molecular characteristics such as CDKN2A copy number
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Table 1. Selected studies of sequenced or combined targeted therapy with immune checkpoint blockade in
metastatic melanoma.
Study (year)

Study design

Patients (n)

Modality of treatment

Presence of
intracranial
metastases

Primary end
point

Survival results

Ref.

Gutzmer
et al. (2020)

Prospective randomized
double blinded Phase III

256

Combination
atezolizumab,
vemurafenib and
cobimetinib

Yes (5 patients in
the study arm)

PFS

15.1 vs 10.6 months

[16]

Puzanov
et al. (2020)

Post hoc Pooled analysis of 271
three clinical trials

Previously treated with
BRAFi with or without
MEKi and later were
treated with
pembrolizumab

Yes (46 patients in
the study arm)

ORR, PFS, OS

Lower ORR, PFS and
OS†

[17]

Dummer et al.
(2020)

Single arm safety run in
36
from Phase III COMBI-I trial

Combination
spartalizumab,
dabrafenib, trametinib

Not included

Dose limiting
toxicity
biomarker
analysis‡

24 months PFS was
41%

[18]

Burton et al. (2019)

Single arm Phase II

24

Combination nivolumab,
dabrafenib, trametinib

Included

Safety and
ORR§

Not provided

[19]

Ribas et al. (2015)

Phase I

50

Combination durvalumab,
dabrafenib, trametinib

Not included

Safety

Not provided

[20]

Amin et al. (2016)

Phase II

46

Vemurafenib followed by
ipilimumab

Not included

Safety

mPFS was
4.5 months

[21]

† Baseline

characteristics were significantly different in the compared subgroups.
was a secondary end point in the study.
§ ORR was 89% in 19 evaluable patients.
BRAFi: BRAF inhibitor; MEKi: MEK inhibitor; PFS: Progression-free survival; ORR: Objective response rate; OS: Overall survival.
‡ PFS

loss can aid in planning treatment (favoring a short course with targeted therapy and considering other treatments
prior to disease progression). While this case report provides proof-of-concept, further clinical trials are needed to
confirm stated conclusions.
Future perspective
To date, the management of patients with metastatic intracranial melanoma and symptomatic disease remains
challenging with very limited therapeutic options. The use of steroids to relieve symptom associated morbidity
might hinder the efficacy of ICB. The role of targeted therapy in such patients with BRAF-mutated melanoma
is a possible avenue to circumvent the use of steroids. Research is currently ongoing to investigate the efficacy
and safety of and approach combining versus sequencing BRAF-MEK inhibitors and ICB in metastatic melanoma
which will offer further insight on the possible role of utilizing short-term targeted therapy prior to ICB in patients
with symptomatic intracranial melanoma.
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